Working… Menu

Sunitinib Malate Before and After Surgery in Treating Patients With Previously Untreated Metastatic Kidney Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01024205
Recruitment Status : Completed
First Posted : December 2, 2009
Last Update Posted : August 12, 2013
Information provided by:
National Cancer Institute (NCI)

Brief Summary:

RATIONALE: Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving sunitinib malate before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving sunitinib malate after surgery may kill any tumor cells that remain after surgery.

PURPOSE: This phase II trial is studying how well giving sunitinib malate before and after surgery works in treating patients with metastatic kidney cancer.

Condition or disease Intervention/treatment Phase
Kidney Cancer Drug: sunitinib malate Other: laboratory biomarker analysis Procedure: adjuvant therapy Procedure: neoadjuvant therapy Procedure: therapeutic conventional surgery Phase 2

Detailed Description:



  • Determine if neoadjuvant sunitinib malate can achieve a clinical benefit of 70% or more to the primary renal tumor prior to surgery and adjuvant sunitinib malate in patients with metastatic renal cancer.


  • Determine the time to radiological progression in these patients.
  • Determine the overall survival of these patients.
  • Determine the proportion of patients suitable for nephrectomy after neoadjuvant sunitinib malate.
  • Determine the translational endpoints.

OUTLINE: Patients receive oral sunitinib malate once daily on days 1-28. Treatment repeats every 6 weeks for 3 courses. Approximately 2 weeks later, patients undergo a standard radical nephrectomy with lymph node dissection. Beginning at least 2 weeks after surgery, patients receive oral sunitinib malate on days 1-28. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.

Blood and tissue samples may be collected periodically for laboratory studies.

After completion of study treatment, patients are followed every 2 months.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 43 participants
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Upfront Sunitinib (SU011248) Therapy Followed by Surgery in Patients With Metastatic Renal Cancer: A Pilot Phase II Study [SuMR]
Study Start Date : August 2007
Actual Primary Completion Date : August 2010
Actual Study Completion Date : May 2012

Primary Outcome Measures :
  1. Neoadjuvant sunitinib malate achieving a clinical benefit of ≥ 70%

Secondary Outcome Measures :
  1. Time to radiological progression
  2. Overall survival
  3. Proportion of patients suitable for nephrectomy after neoadjuvant sunitinib malate

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Histologically confirmed renal cell carcinoma

    • Measurable metastatic disease on CT/MRI imaging
    • Patients with suspicion of renal cancer on radiology must have a biopsy to confirm diagnosis of clear cell disease
  • No prior therapy for renal cancer
  • Judged by the treating physician to have the potential to derive clinical benefit from this treatment


  • ECOG performance status 0-2
  • Absolute neutrophil count ≥ 1 x 10^9/L (without growth factor support)
  • Platelet count ≥ 75 x 10^9/L
  • Total bilirubin ≤ 2 times upper limit of normal (ULN) (except for patients with Gilbert disease)
  • Serum creatinine ≤ 2 times ULN
  • Serum transaminases < 5 times ULN
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception during and for ≥ 28 days after completion of study therapy
  • Willing and able to comply with scheduled visits, treatment plan, and laboratory tests and other study procedures
  • No congestive heart failure, myocardial infarction, or coronary artery bypass graft within the past 6 months, or ongoing severe or unstable arrhythmia requiring medication
  • No other severe acute or chronic medical or psychiatric condition, or abnormal laboratory results that would impart, in the judgement of the investigator, excess risk associated with study participation or study drug administration or would make the patient inappropriate for entry into this study


  • See Disease Characteristics
  • At least 7 days since prior and no concurrent potent CYP3A inhibitors, including any of the following:

    • Ketoconazole
    • Itraconazole
    • Clarithromycin
    • Erythromycin
    • Diltiazem
    • Verapamil
    • Delavirdine
    • Indinavir
    • Saquinavir
    • Ritonavir
    • Atazanavir
    • Nelfinavir
  • At least 12 days since prior and no concurrent potent CYP3A inducers, including any of the following:

    • Rifampin
    • Rifabutin
    • Carbamazepine
    • Phenobarbital
    • Phenytoin
    • St. John's wort
    • Efavirenz
    • Tipranavir
  • Concurrent radiotherapy allowed provided sunitinib malate is stopped one day before and resumed one day after radiotherapy
  • Concurrent coumarin-derivative anticoagulants (e.g., warfarin) allowed (≤ 2 mg/day) for prophylaxis of thrombosis
  • No concurrent treatment with a drug having proarrhythmic potential (i.e., terfenadine, quinidine, procainamide, disopyramide, sotalol, probucol, bepridil, haloperidol, risperidone, indapamide, or flecainide)
  • No other concurrent investigational drug or participation in another clinical trial (unless approved by the sponsor)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01024205

Layout table for location information
United Kingdom
Orchid Clinical Trials Group at Barts and the London School of Medicine and Dentistry
London, England, United Kingdom, EC1M 6BQ
Sponsors and Collaborators
Barts and the London School of Medicine and Dentistry
Layout table for investigator information
Principal Investigator: Thomas Powles, MD, MRCP Barts and the London School of Medicine and Dentistry
Publications of Results:
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information Identifier: NCT01024205    
Other Study ID Numbers: OCTG-SuMR
CDR0000660317 ( Registry Identifier: PDQ (Physician Data Query) )
First Posted: December 2, 2009    Key Record Dates
Last Update Posted: August 12, 2013
Last Verified: July 2011
Keywords provided by National Cancer Institute (NCI):
clear cell renal cell carcinoma
stage IV renal cell cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Kidney Neoplasms
Carcinoma, Renal Cell
Urologic Neoplasms
Urogenital Neoplasms
Neoplasms by Site
Kidney Diseases
Urologic Diseases
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Antineoplastic Agents
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action